-
2023-504251-27-00
7
2024-05-27
Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mut
-
2023-505043-39-00
5
2024-05-24
Duchenne Muscular Dystrophy
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2023-505602-42-00
4
2024-04-30
Spinal Muscular Atrophy (SMA)
-
2022-502576-23-00
1
2024-04-17
Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive
-
2023-510506-41-00
4
2024-04-15
Locally advanced, unresectable non-small-cell lung cancer (NSCLC)
(Sta
-
2022-501725-21-00
1
2024-04-12
Neuroblastoma
-
2023-503317-29-00
5
2024-04-12
Metastatic renal cell carcinoma (mRCC)
-
2023-504374-38-00
5
2024-04-12
Locally advanced cervical cancer
-
2024-515267-59-00
4
2024-04-07
Acute myeloid leukemia
-
2023-503208-94-00
6
2024-04-04
Prostate cancer
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2023-505267-36-00
5
2024-03-15
Glioblastoma
-
2023-503521-19-00
5
2024-02-09
Duchenne muscular dystrophy (DMD)
-
2024-511537-35-00
9
2024-02-09
Metastatic castration-resistant prostate cancer (mCRPC)
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2024-516634-35-00
6
2024-02-01
Convulsive or nonconvulsive benzodiazepine-resistant (established) sta
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2023-504322-19-00
5
2024-01-10
Patients in the intensive care unit on ventilation with pneumonia and
-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2024-515127-11-00
4
2023-12-21
hepatocellular carcinoma
-
2022-503114-23-00
3
2023-12-19
Breast Cancer
-
2022-502332-39-00
4
2023-11-15
Tuberous sclerosis complex (TSC)